Trastuzumab biosimilar - Allergan/Amgen

Drug Profile

Trastuzumab biosimilar - Allergan/Amgen

Alternative Names: ABP-980

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Synthon
  • Developer Allergan; Amgen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase Unknown Gastric cancer

Most Recent Events

  • 14 Feb 2017 Investigation in Gastric cancer (IV)
  • 01 Jan 2017 Amgen completes a phase III trial in Breast cancer in Bulgaria, Canada, Germany, Greece, Hungary, Italy, Poland, Romania, Russia, Spain, Belarus, Brazil, Chile, Mexico, Serbia, South Africa, Ukraine and the UK (NCT01901146)
  • 21 Jul 2016 Adverse events data from a phase III trial in Breast cancer released by Amgen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top